Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
48 Results for "
hepatic dysfunction
" in MedChemExpress (MCE) Product Catalog:
Products (48)
48 Results for "hepatic dysfunction" in MCE Product Catalog:
8
Research Areas:
Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline maleate induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline maleate can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline maleate can be used in the research of cancers, and cardiovascular disease like angina .
8
Research Areas:
Perhexiline is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline can be used in the research of cancers, and cardiovascular disease like angina .
4
4
Category:
Vitaceae Extract Plant Microorganism Disease Research Fields Inflammation/Immunology Vitis vinifera cv. Zalema Extract Saccharides Monosaccharides
Target:
4
4 Cited Publications
Synonyms: γ-Glu-Cys TFA
4
4 Cited Publications
Research Areas:
MitoTEMPOL is a mitochondria-targeted superoxide scavenger. MitoTEMPOL accumulates in mitochondria via membrane potential and locally scavenges superoxide anions. MitoTEMPOL alleviates hepatic oxidative stress and alterations in genes related to autophagy in STZ (HY-13753)-induced diabetic models. MitoTEMPOL inhibits diaphragmatic mitochondrial dysfunction and activation of proteolytic pathways in sepsis models. MitoTEMPOL also alleviates AGEs (HY-NP165)-induced ferritinophagy-dependent ferroptosis in human umbilical vein endothelial cells. MitoTEMPOL is used in research related to diabetes, sepsis, and vascular endothelial ferroptosis .
2
Target:
Research Areas:
2
2 Cited Publications
Research Areas:
K284-6111 is a high-affinity and orally active CHI3L1 inhibitor, and inhibits CHI3L1 expression. K284-6111 inhibits ERK and NF-κB pathway. K284-6111 suppresses nuclear translocation of p50 and p65, and phosphorylation of IκB. K284-6111 improves memory dysfunction by alleviating amyloidogenesis and neuroinflammation, with the reduction of inflammatory proteins (eg: iNOS, COX-2, GFAP, and Iba-1). K284-6111 reduces atopic-like skin inflammation and inhibits LPS (HY-D1056) -induced liver injury. K284-6111 can be used for the study of Alzheimer's diseases and sepsis like hepatic injury .
1
1 Cited Publications
Cat. No.: HY-N0732
CAS No.: 37905-08-1
1
1 Cited Publications
Cat. No.: HY-N0909
CAS No.: 80418-25-3
Synonyms: 20(S)-Notoginsenoside R2; Ginsenoside Ng-R2
Cat. No.: HY-W018587
CAS No.: 26040-51-7
Target:
Mitochondrial Metabolism Cytochrome P450 TNF Receptor Interleukin Related HSP LDLR Eukaryotic Initiation Factor (eIF) ClpP
Research Areas:
TBPH is a brominated flame retardant. TBPH enhances hepatic steatosis, inflammation, and fibrosis in mice with nonalcoholic steatohepatitis (NASH). TBPH induces dysregulation of phospholipid metabolism, reducing cardiolipin (CL) and phosphatidylserine (PS) levels. TBPH leads to impaired endoplasmic reticulum-mitochondria (ER-Mito) contacts, subsequently causing mitochondrial dysfunction. TBPH induces lung injury through an inflammatory response mediated by mitochondria-derived ds-DNA. TBPH can be used to study the role of MFN2-mediated ER-mitochondria contacts in lipid metabolism homeostasis .
Cat. No.: HY-W779068
CAS No.: 60237-34-5
Target:
Category:
Human Gut Microbiota Metabolites Natural Products Metabolic Disease Endogenous metabolite Disease Research Fields
Target:
Cat. No.: HY-142026
CAS No.: 142449-89-6
Synonyms: (+)-Vitisin A
Cat. No.: HY-135174
CAS No.: 13081-14-6
Synonyms: L-CySSG; CYSH-GSH
Research Areas:
L-Cysteine-glutathione disulfide (L-CySSG; CYSH-GSH) is a thiol-modified glutathione prodrug with antioxidant, anti-inflammatory, and oral activities. L-Cysteine-glutathione disulfide reduces the production of mitochondrial ROS, and alleviates oxidative stress, inflammatory responses, and elevated levels of hepatic enzymes. L-Cysteine-glutathione disulfide prevents liver injury in mice induced by high-fat diet or LPS. The expression level of L-Cysteine-glutathione disulfide changes during tuberculosis infection, so it can serve as a biomarker for pulmonary tuberculosis. L-Cysteine-glutathione disulfide is applicable to research on pulmonary tuberculosis, metabolic dysfunction-associated steatotic liver disease, and liver injury .
Cat. No.: HY-113360
CAS No.: 59132-32-0
Category:
Human Gut Microbiota Metabolites Endogenous metabolite Disease Research Fields Inflammation/Immunology Steroids
Target:
Cat. No.: HY-172661
CAS No.: 2661053-09-2
Research Areas:
Kylo-0603 is an orally active thyroid hormone receptor β (THR-β) agonist with an EC50 of 31.07 nM against human targets, and it exhibits much higher selectivity for THR-β than for THR-α. Kylo-0603 enables hepatocyte-targeted delivery via GalNAc modification. Kylo-0603 reduces serum cholesterol and low-density lipoprotein cholesterol levels. Kylo-0603 alleviates hepatic steatosis, inflammatory responses, hepatocyte ballooning, and non-alcoholic steatohepatitis activity scores. Kylo-0603 inhibits the progression of hepatic fibrosis. Kylo-0603 can be used for research on metabolic dysfunction-associated steatohepatitis (MASH) .
Cat. No.: HY-113402R
CAS No.: 636-58-8
Synonyms: γ-Glu-Cys (Standard)
Cat. No.: HY-148626
CAS No.: 1233353-74-6
Research Areas:
CVI-LM001 is an orally active PCSK9 inhibitor. CVI-LM001 inhibits PCSK9 transcription and suppresses PCSK9 mRNA expression, reducing circulating PCSK9. CVI-LM001 stabilizes LDLR mRNA and increases hepatic LDLR expression. CVI-LM001 induces hepatic AMPK phosphorylation, alleviates hepatic steatosis, reduces triglyceride synthesis, promotes fatty acid oxidation, and lowers serum and hepatic lipid levels. CVI-LM001 can be used for research on hypercholesterolemia and metabolic dysfunction-associated steatotic liver disease .
Cat. No.: HY-178015
CAS No.: 3051970-23-8
Target:
Research Areas:
THR-β agonist 11 is an orally active and selective thyroid hormone receptor (THR-β) agonist. THR-β agonist 11 shows potent cholesterol-lowering activity in cholesterol-fed rats. THR-β agonist 11 significantly reduces serum total TG, LDL-cholesterol, liver total TC and TG levels, and alleviates hepatic steatosis, inflammation and fibrosis in HFD-CCl4-induced Metabolic dysfunction-associated steatohepatitis (MASH) model mice. THR-β agonist 11 can be used for the study of metabolic dysfunction-associated steatohepatitis (MASH) and other fibrotic diseases .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
